TriSalus Life Sciences (NASDAQ:TLSI) Shares Climb 0.8% - What's Next?

Key Points

• TriSalus shares rose 0.8% to $3.62 in mid-day trading, with volume 39% below the average session level. The company has a market capitalization of approximately $222.9 million.
• Analyst sentiment is mixed: three firms rate the stock a Buy, one rates it Hold, and one rates it Sell. The consensus rating is Hold, with a target price of $10.20, substantially above the recent share price.
• TriSalus reported quarterly revenue of $11.41 million, ahead of the $10.27 million consensus estimate, while its adjusted loss of $0.16 per share matched expectations. Institutional investors recently increased their positions, though they collectively own only 2.58% of the company.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report)'s stock price was up 0.8% during mid-day trading on Monday. The stock traded as high as $3.81 and last traded at $3.62. 111,786 shares changed hands during mid-day trading, a decline of 39% from the average session volume of 183,843 shares. The stock had previously closed at $3.59.

Analyst Ratings Changes

A number of research firms have recently issued reports on TLSI. HC Wainwright raised their price objective on TriSalus Life Sciences from $11.00 to $12.00 and gave the company a "buy" rating in a research report on Wednesday, September 23rd. Guggenheim set a $12.00 target price on TriSalus Life Sciences in a report on Wednesday, September 23rd. Zacks Research upgraded TriSalus Life Sciences to a "hold" rating in a research note on Thursday, September 10th. Stifel Nicolaus set a $12.00 price target on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $10.20.

TriSalus Life Sciences Stock Up 0.8%

The firm has a market cap of $222.92 million, a P/E ratio of -2.78 and a beta of 0.47. The firm's fifty day moving average is $4.59 and its 200 day moving average is $4.47. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The company had revenue of $11.41 million during the quarter, compared to the consensus estimate of $10.27 million. As a group, equities research analysts anticipate that TriSalus Life Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of large investors have recently made changes to their positions in TLSI. First Light Asset Management LLC boosted its stake in TriSalus Life Sciences by 29.3% in the 2nd quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company's stock valued at $29,814,000 after purchasing an additional 1,485,664 shares during the period. BlackRock Inc. bought a new position in TriSalus Life Sciences during the 2nd quarter worth $12,099,000. Nantahala Capital Management LLC bought a new position in TriSalus Life Sciences during the 2nd quarter worth $4,550,000. State Street Corp increased its position in TriSalus Life Sciences by 86.3% during the 2nd quarter. State Street Corp now owns 610,963 shares of the company's stock worth $2,780,000 after buying an additional 282,943 shares during the period. Finally, Empire Financial Management Company LLC lifted its holdings in shares of TriSalus Life Sciences by 316.9% during the first quarter. Empire Financial Management Company LLC now owns 300,275 shares of the company's stock worth $1,201,000 after buying an additional 228,248 shares in the last quarter. Institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.